CD177 and cancer: It is important to note that bypassing tyrosine kinases responsible for Stat5 phosphorylation by utilizing direct Stat5 inhibitor would be advantageous for therapy development for Stat5-regulated cancers because targeting Stat5 directly is likely to cause less off-target side effects than targeting kinases or cell surface receptors.